QC
DRUG

Quadrature Capital’s Bright Minds Biosciences DRUG Stock Holding History

Quadrature Capital’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,498
Closed -$474K – 1702
2026
Q1 		$474K Buy
+6,498
New +$523K 0.01% 809

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Quadrature Capital's DRUG Position: Q2 2026 in Review

Quadrature Capital sold out of Bright Minds Biosciences (DRUG) in Q2 2026, closing a stake of 6,498 shares — an estimated $474K sold.

Quadrature Capital first reported a position in DRUG in Q1 2026 and held it in 1 quarter. The position peaked at $474K in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Quadrature Capital reported no remaining Bright Minds Biosciences position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 6,498 Bright Minds Biosciences shares in Q2 2026, an estimated $474K.
  • Quadrature Capital first reported a position in Bright Minds Biosciences in Q1 2026 and held it in 1 quarter.
  • Quadrature Capital's Bright Minds Biosciences position peaked at $474K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.